Paradigm Biopharmaceuticals Ltd.ASX: PAR

Paradigm Achieves 50% Patient Dosing in Phase 3

Mar 31, 2026 at 1:43 AM UTC · Issued by Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd has released a press release.

View Attachment